HCPLive Network

Medicare Will Cover Primary Care-ordered Hepatitis C Testing

WEDNESDAY, June 11, 2014 (HealthDay News) -- Medicare will cover primary care provider-ordered hepatitis C virus testing for adults, according to a statement released by the Centers for Medicare and Medicaid Services (CMS) and discussed in an article published online June 3 in Medical Economics.

The author of the article, Donna Marbury, writes that CMS testing will include a single screening for adults born between 1945 and 1965 and repeat screenings for high-risk adults. Disabled adults younger than 65 years are also eligible for testing. The tests must be ordered by a primary care provider. Settings that are not considered primary care settings include emergency departments, inpatient hospital settings, and independent diagnostic testing facilities.

According to Marbury, increased attention to hepatitis C virus testing began after the US Preventive Services Task Force recommended that all Baby Boomers be tested, irrespective of risk factors. However, the high cost of hepatitis C virus treatments has become an issue for debate, with many questioning whether the high cost of treatment is worth it.

"As preventive services gain recognition of their potential to improve the health status of the individual, we believe the primary care provider is in the unique position to provide a comprehensive and coordinated approach to Medicare beneficiaries' health care and this coordinated approach will help ensure the best outcomes for these services," CMS said in response to comments questioning whether testing should be expanded to other practitioners and medical settings, according to the Medical Economics article.

More Information

Copyright © 2014 HealthDay. All rights reserved.

Further Reading
Complication rates are similar for single-level anterior cervical discectomy and fusions, whether the procedure is performed by a neurosurgeon or orthopedic surgeon, according to a study published in the Sept. 15 issue of Spine.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
More Reading